Mimedx (MDXG) Long-Term Investments (2014 - 2015)

Mimedx's (MDXG) quarterly Long-Term Investments came in at $2.5 million in Q1 2015, down 23.08% quarter-over-quarter from $3.2 million in Q4 2014.

Mimedx (MDXG) Long-Term Investments (2014 - 2015) Analysis & Trends

Mimedx has disclosed Long-Term Investments across 2 years of filings, most recently posting $2.5 million for Q1 2015.

Long-Term Investments for Q1 2015 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2015 was $2.5 million (changed N/A YoY), and the FY2014 annual result was $3.2 million, changed N/A from the prior year.
Long-Term Investments came in at $2.5 million for Q1 2015 at Mimedx, down from $3.2 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $3.2 million in Q4 2014 to a low of $2.5 million in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Mimedx	546.28 Mn	386.51 Mn	41.62 Mn	-

Download Data

Date	Value
Mar 31, 2015	2.50 Mn
Dec 31, 2014	3.25 Mn